QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:ICAD

iCAD (ICAD) Stock Forecast, Price & News

$1.25
-0.03 (-2.34%)
(As of 06/6/2023 ET)
Compare
Today's Range
$1.22
$1.33
50-Day Range
$1.14
$1.48
52-Week Range
$1.05
$4.66
Volume
348,050 shs
Average Volume
151,712 shs
Market Capitalization
$31.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.90

iCAD MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
212.0% Upside
$3.90 Price Target
Short Interest
Healthy
1.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$52,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Computer And Technology Sector

238th out of 606 stocks

Surgical & Medical Instruments Industry

27th out of 97 stocks


ICAD stock logo

About iCAD (NASDAQ:ICAD) Stock

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Receive ICAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCAD and its competitors with MarketBeat's FREE daily newsletter.

ICAD Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Recap: icad Q1 Earnings
Here's what Wall Street expects from icad's earnings report
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
iCAD (ICAD) to Release Quarterly Earnings on Monday
Analyst Expectations for icad's Future
JMP Securities Reaffirms Their Buy Rating on iCAD (ICAD)
Oppenheimer Trims iCAD (NASDAQ:ICAD) Target Price to $4.00
iCAD, Inc. (NASDAQ:ICAD) Insider Buys $52,000.00 in Stock
See More Headlines

ICAD Price History

ICAD Company Calendar

Last Earnings
3/28/2023
Today
6/06/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:ICAD
Employees
136
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.90
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+212.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-13,660,000.00
Pretax Margin
-53.44%

Debt

Sales & Book Value

Annual Sales
$26.20 million
Book Value
$1.38 per share

Miscellaneous

Free Float
22,011,000
Market Cap
$31.81 million
Optionable
Optionable
Beta
1.14

Social Links


Key Executives

  • Dana R. Brown
    Executive Chairman, President & CEO
  • Michelle Strong
    Chief Operations Officer
  • Eric Lonnqvist
    Chief Financial Officer
  • Jonathan GoJonathan Go
    Chief Technology Officer
  • William Keyes
    Senior Vice President-US Commercial Sales-AI













ICAD Stock - Frequently Asked Questions

Should I buy or sell iCAD stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICAD shares.
View ICAD analyst ratings
or view top-rated stocks.

What is iCAD's stock price forecast for 2023?

4 brokerages have issued 1-year price objectives for iCAD's stock. Their ICAD share price forecasts range from $2.50 to $6.00. On average, they anticipate the company's share price to reach $3.90 in the next year. This suggests a possible upside of 212.0% from the stock's current price.
View analysts price targets for ICAD
or view top-rated stocks among Wall Street analysts.

How have ICAD shares performed in 2023?

iCAD's stock was trading at $1.83 at the beginning of 2023. Since then, ICAD stock has decreased by 31.7% and is now trading at $1.25.
View the best growth stocks for 2023 here
.

When is iCAD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ICAD earnings forecast
.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) issued its quarterly earnings results on Tuesday, March, 28th. The technology company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. The technology company earned $6.49 million during the quarter, compared to the consensus estimate of $6.53 million. iCAD had a negative trailing twelve-month return on equity of 37.50% and a negative net margin of 53.01%.

What guidance has iCAD issued on next quarter's earnings?

iCAD issued an update on its fourth quarter 2022 earnings guidance on Monday, March, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.50 million-$6.50 million, compared to the consensus revenue estimate of $6.61 million.

What is Michael Klein's approval rating as iCAD's CEO?

4 employees have rated iCAD Chief Executive Officer Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among the company's employees.

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

Who are iCAD's major shareholders?

iCAD's stock is owned by a variety of institutional and retail investors. Top institutional investors include Granahan Investment Management LLC (8.51%), Portolan Capital Management LLC (3.61%), Greenwood Capital Associates LLC (1.27%), General American Investors Co. Inc. (0.79%), Perritt Capital Management Inc. (0.79%) and Renaissance Technologies LLC (0.75%). Insiders that own company stock include Andy Sassine, Charles Ross Carter, Dana R Brown, Jonathan Go, Michael S Klein, R Scott Areglado, Stacey M Stevens, Susan Alyson Wood and Timothy Norris Irish.
View institutional ownership trends
.

How do I buy shares of iCAD?

Shares of ICAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $1.25.

How much money does iCAD make?

iCAD (NASDAQ:ICAD) has a market capitalization of $31.81 million and generates $26.20 million in revenue each year. The technology company earns $-13,660,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does iCAD have?

The company employs 136 workers across the globe.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The official website for the company is www.icadmed.com. The technology company can be reached via phone at (603) 882-5200, via email at jeremy@lifesciadvisors.com, or via fax at 603-880-3843.

This page (NASDAQ:ICAD) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -